Navigation Links
Amicus Therapeutics Announces First Quarter 2008 Financial Results
Date:5/13/2008

ients with evaluable GCase data, and 5 of the 6 patients without a clear increase were either in the lowest dose cohort or the cohort dosed least frequently. As expected in this short term study, the levels of relevant hematological markers of Gaucher disease remained stable.

Amicus has amended the protocol for the 6-month Phase 2 clinical trial of Plicera patients naive to ERT to include modified doses and dose regimens. Amicus expects the results of this study to be available in 2009. In addition, in the second half of 2008, the Company expects to initiate a longer-term study in individuals switching from ERT to Plicera.

Pompe Disease:

AT2220 (1-deoxynojirimycin HCl) is an investigational, oral therapeutic drug candidate being developed for the treatment of Pompe disease. At the ACMG meeting in March, clinical investigators presented encouraging results from an ex vivo response study in cells from patients with Pompe disease as well as three Phase 1 clinical trials of AT2220 in healthy volunteers. The ex vivo response study was designed to test the effect of AT2220 on various Pompe mutations. Blood and skin samples were collected from 30 Pompe patients (26 adults, 3 juveniles and 1 infant) with a variety of different mutations in acid alpha-glucosidase (GAA), the target enzyme in Pompe disease. Cells from these samples where then treated with AT2220. Of the 26 patients with available data, 24 had cells that showed a dose responsive increase in GAA levels including 22 patients who had at least 1 copy of the common splice site mutation IVS1-13T > G. Data from the Phase 1 trials in a total of 72 healthy volunteers showed that AT2220 was generally safe and well tolerated at all doses.

In the second quarter of 2008, Amicus plans to initiate a Phase 2 clinical trial of AT2220 in patients with Pompe disease. The Company also plans to consider the initiation of a clinical trial of AT2220-ERT combination treatment in Pompe patients later in 2008
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... and SAN JOSE, California , January ... company developing antibody-drug conjugates for cancer, today announced the appointment ... Directors. Dr Reynolds has over 20 years, development experience gained ... at Seattle Genetics. "I am delighted to welcome ...
(Date:1/15/2014)... Two champions of science, technology, engineering, and mathematics ... competition for middle and high school students designed to ... The competition presents students with real-world problems experienced by ... and Sciences is a program administered by the ...
(Date:1/15/2014)... 15, 2014 AudioNotch is the internet's ... for the treatment of tinnitus. Patients listen to sound ... over a period of weeks to months, their tinnitus volume ... two forms: Notched Music and Notched White Noise. Now, AudioNotch ...
(Date:1/14/2014)... WASHINGTON , Jan. 14, 2014  3D Communications, a leading provider ... scientific, regulatory, business, and media events in the United ... its former associate Virginia Cox , JD, is returning to ... Virginia Cox re-joins 3D after more than two years ...
Breaking Biology Technology:Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5Former FDA Associate Commissioner Returns To 3D Communications 2
... RVX, ORLANDO, FL, Nov. 5 /PRNewswire-FirstCall/ ... announce today key scientific data,was presented in ... of,RVX-208, at the American Heart Association Scientific ... RVX-208 Increases,Serum Levels of ApoA-I and Improves ...
... -,- 3Q07 Net Income Increased 58% Compared to 3Q06 to $11.9 Million, or ... ... Provides Financial Outlook for 2007 and 2008 -, NEW YORK, Nov. 5 ... of,plant-based pharmaceutical and nutraceutical products, today announced,financial results for the third quarter of ...
... Third ... Compared to Third Quarter 2006 FFO Per Share (Diluted) of ... $1.32 - Third Quarter 2007 Total Revenues up 23%, FFO Available to Common ... Stockholders up 21% - Third Quarter 2007 Earnings Per Share (Diluted) of $0.68, ...
Cached Biology Technology:Reverse Cholesterol Transport by RVX-208 a Small Molecule for ApoA-I Production Increase Presented at American Heart Association Scientific Meeting 2Reverse Cholesterol Transport by RVX-208 a Small Molecule for ApoA-I Production Increase Presented at American Heart Association Scientific Meeting 3American Oriental Bioengineering Reports Third Quarter 2007 Financial Results 2American Oriental Bioengineering Reports Third Quarter 2007 Financial Results 3American Oriental Bioengineering Reports Third Quarter 2007 Financial Results 4American Oriental Bioengineering Reports Third Quarter 2007 Financial Results 5American Oriental Bioengineering Reports Third Quarter 2007 Financial Results 6American Oriental Bioengineering Reports Third Quarter 2007 Financial Results 7American Oriental Bioengineering Reports Third Quarter 2007 Financial Results 8Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 2Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 3Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 4Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 5Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 6Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 7Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 8Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 9Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 10Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 11Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 12Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 13Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 14Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 15Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 16Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 17Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 18Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 19Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 20Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 21Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 22Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 23Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 24Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 25Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 26Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 27
(Date:4/23/2014)... Angeles, London (April 23, 2014). "I think one can argue ... pathwayas well as doing everything else that we canthen we ... Tom Wigley, one of the world,s foremost climate researchers, in ... , published by SAGE. Refusing to take significant action on ... eventually be needed to address the problem, Wigley explains in ...
(Date:4/22/2014)... Yale researchers will lead a five-year, $3 million study ... is affecting the transport of dissolved organic matter (DOM) ... could alter the chemical composition and water quality of ... from the National Science Foundation,s MacroSystems Biology program, researchers ... watershed, which begins in Canada and runs through five ...
(Date:4/22/2014)... 22, 2014) Biotechnology scientists must be aware of ... and licensing guidelines, according to a new paper from ... in the current issue of the journal Regenerative ... 2013 U.S. Supreme Court ruling in the case Association ... occurring genes are unpatentable. The court case and rulings ...
Breaking Biology News(10 mins):Is nuclear power the only way to avoid geoengineering? 2Connecticut River watershed study will assess impacts of extreme rain events 2Connecticut River watershed study will assess impacts of extreme rain events 3New patenting guidelines are needed for biotechnology 2New patenting guidelines are needed for biotechnology 3
... might tell potential suitors, "I like the way you ... worms send their valentines via signals known as pheromones, ... to a study published Wednesday (July 23) in the ... University of Florida, Cornell University, the California Institute of ...
... July 23, 2008. A fire is currently burning through a ... 2 years ago. Managers used data and analysis from the ... implementation of treatments near where the Cold Springs fire is ... of the Cascade Range in Washington, and covers about 15,000 ...
... manure into a domestic renewable fuel source could generate ... of North America,s entire consumption needs and lead to ... to US research published today, Thursday, 24 July, in ... The journal paper, ,Cow Power: The Energy and ...
Cached Biology News:Mate or hibernate? That's the question worm pheromones answer 2Mate or hibernate? That's the question worm pheromones answer 3Landscape study may offer solutions for fire managers 2Cow power could generate electricity for millions 2